摘要
文章综述了单抗药物用于临床肿瘤治疗的研究进展。开发一个成功的抗肿瘤单抗药物应从以下几方面考虑 :(1)选择特异的肿瘤抗原 ;(2 )制备人源化单抗以降低单抗药物的免疫原性 ;(3)利用抗体工程改造抗体结构以延长半衰期 ;(4)改进给药方式以提高抗体药物在肿瘤组织的局部浓度 ;(5 )提高单抗药物的抗肿瘤活性 ;(6 )进一步提高单抗药物的选择性。还简述了单抗药物抗肿瘤的可能机制及单抗药物的前景展望。
This paper reviews some development in monoclonal antibody's anti tumor clinlical therapy. To explore a successful anti tumor monoclone antibody medicine, following aspects should be considered: (1) to choose the specific tumor antigen (2) Producing humanized or human antibody to reduce HAMA effection (3)To reform the structure of antibody using antibody engineering in order to prolong the half life time of medicine (4) Improving the administration method in order to raise the concentration of medicine in tumor tissue (5) To improve the anti tumor effection (6)improving the medicine's choice. In additional, the anti tumor mechanism and prospect of monoclonal antibody medicine were discussed in this paper.
出处
《药物生物技术》
CAS
CSCD
2003年第3期194-198,共5页
Pharmaceutical Biotechnology
关键词
抗肿瘤
单抗
人抗鼠抗体反应
临体治疗
Monoclone antibody, Aanti tumor, HAMA effection, Clinlical therapy